Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics, Inc. Chief Medical Officer Jesse Wayne Hall reported routine equity compensation activity involving restricted stock units (RSUs). On May 1, 2026, RSUs covering 36,375 shares were converted into common stock at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase.
On the same date, 9,330 common shares were withheld by Aclaris to cover Hall’s tax withholding obligations tied to the RSU vesting, a non‑market disposition classified as a tax-withholding transaction. After these events, Hall directly held 27,045 shares of common stock and 109,125 RSUs.
Each RSU represents a contingent right to receive one share of Aclaris common stock. The underlying RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of May 1, 2025, subject to Hall’s continued service under the company’s 2024 Inducement Plan.
Aclaris Therapeutics announced positive full top line results from a first‑in‑human Phase 1a trial of ATI‑052, a bispecific antibody targeting TSLP and IL‑4Rα. The study in healthy volunteers tested single doses up to 720 mg and multiple weekly doses up to 480 mg and showed a favorable safety, pharmacokinetic, and pharmacodynamic profile with an estimated half‑life of about 45 days, supporting the potential for dosing as infrequently as every three months.
The company is enrolling Phase 1b proof‑of‑concept trials of ATI‑052 in asthma and atopic dermatitis, with top line data planned for the second half of 2026 and a Phase 2b asthma program expected to start in the fourth quarter of 2026. Aclaris also selected lichen planus (LP) as the lead indication for its oral ITK/JAK3 inhibitor ATI‑2138 and plans a multi‑part Phase 2b basket trial in LP subtypes beginning in the second half of 2026, citing a potential U.S. market opportunity above $1.0 billion and up to $4.0 billion.
Aclaris Therapeutics, Inc. insider-related entity executes open-market sale. On behalf of BML Investment Partners, L.P., a fund associated with ten percent owner Michael Leonard, 300,000 shares of Aclaris common stock were sold in an open-market transaction at $4.53 per share. Following this sale, the fund’s indirect holdings reported as beneficially owned by Mr. Leonard totaled 13,950,000 shares, which he reports with a disclaimer of beneficial ownership except to the extent of his pecuniary interest.
BML Investment Partners, L.P. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 13,950,000 shares of Aclaris Therapeutics common stock, representing 9.9% of the class based on 139,663,680 shares outstanding as disclosed on a DEF 14A dated 4/23/2026. The filing states shared voting and dispositive power over these shares and includes a signature block explaining indirect ownership through BML Capital Management, LLC and Braden M. Leonard, with a disclaimer that the reporting persons do not constitute a statutory group under Rule 13d-5(b)(1).
Aclaris Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 14, 2026, holding 139,663,680 shares of common stock, may vote online using a 16-digit control number.
Three items are up for vote: electing two directors (Anand Mehra and Maxine Gowen) for terms ending in 2029, an advisory “say-on-pay” vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. The board is classified into three classes and currently has eight members, six of whom are independent under Nasdaq rules.
The proxy details 2025 pay for named executive officers, including total compensation of $3,375,591 for CEO Neal Walker, $1,490,790 for CFO Kevin Balthaser, and $1,447,106 for Chief Business Officer James Loerop, combining salary, stock awards, options and bonuses. It also discloses major shareholders such as BML Investment Partners at 10.2% and Biosion, Inc. at 8.1%, outlines board committee responsibilities, insider trading and clawback policies, and explains how votes, broker non-votes and quorum (69,831,841 shares) are determined.
Aclaris Therapeutics ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial interests in 7,626,705 shares of Aclaris common stock, representing 6.3% of the class based on 120,595,189 shares outstanding as of January 30, 2026. The filing states the Fund directly holds the 7,626,705 shares; RA Capital serves as investment adviser with shared voting and dispositive power over those shares. The Reporting Persons disclaim status as a group and include a statement that the Fund has delegated voting and disposition authority with a 61-day notice constraint.
Aclaris Therapeutics Inc receives an amended beneficial ownership filing from The Vanguard Group reporting 0 shares of Common Stock and 0% ownership in this amendment. The filing notes an internal realignment at Vanguard on January 12, 2026 that led certain subsidiaries and divisions to report separately under SEC Release No. 34-39538.
The filing is administrative: it states Vanguard and its covered accounts hold no beneficial shares of Aclaris Common Stock as reported and documents the change in reporting allocation among Vanguard entities. The signature block records filing execution by Ashley Grim, Head of Global Fund Administration.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 9,345,000 shares of Aclaris Therapeutics common stock, representing 7.01% of the class as of March 16, 2026. The filing states the holders have shared voting and dispositive power over 9,345,000 shares and zero sole voting or dispositive power.
The filing explains the percent is calculated using 133,295,189 shares, derived from 120,595,189 shares outstanding as of January 30, 2026 plus 12.7 million shares sold under a sales agreement from March 2, 2026 through March 9, 2026. The report is a joint Schedule 13G filing under Rule 13d-1(k) and lists Deep Track Capital, LP as the relevant entity for control purposes.
Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.